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Cancer and systemic inflammation: treat the
tumour and treat the host
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Determinants of cancer progression and survival are multifactorial and host responses are increasingly appreciated to
have a major role. Indeed, the development and maintenance of a systemic inflammatory response has been consistently
observed to confer poorer outcome, in both early and advanced stage disease. For patients, cancer-associated symptoms are
of particular importance resulting in a marked impact on day-to-day quality of life and are also associated with poorer
outcome. These symptoms are now recognised to cluster with one another with anorexia, weight loss and physical function
forming a recognised cluster whereas fatigue, pain and depression forming another. Importantly, it has become apparent that
these symptom clusters are associated with presence of a systemic inflammatory response in the patient with cancer. Given the
understanding of the above, there is now a need to intervene to moderate systemic inflammatory responses, where present.
In this context the rationale for therapeutic intervention using nonselective anti-inflammatory agents is clear and compelling
and likely to become a part of routine clinical practice in the near future. The published literature on therapeutic intervention
using anti-inflammatory agents for cancer-associated symptoms was reviewed. There are important parallels with the
development of useful treatments for the systemic inflammatory response in patients with rheumatological disease and
cardiovascular disease.
Although the mechanisms determining cancer progression con-
tinue to be of intense interest to scientists and treatments to
oncologists, it is the symptoms associated with cancer progression
that are of most interest to patients. In particular, progressive
appetite loss, weight (lean tissue) loss, fatigue and pain are
extremely debilitating not only impacting on quality of life but also
the response to treatment and survival. However, despite their
importance, research into symptoms associated with cancer has
not been given a high priority by either scientists or clinicians. For
example, MacDonald (2007) pointed out that ‘the number of
abstracts on all aspects of cancer nutrition totalled 15 out of 4917
papers and posters presented at the 2005 Annual Meeting of the
American Society of Clinical Oncology (ASCO); in contrast there
were 106 presentations on gemcitabine (Gemzar) alone. No
progress on this front was evident at the 2006 ASCO meeting,
when the score for nutrition was 10, gemcitabine 86’.
In recent years the importance of the inflammatory responses in
determining disease progression in patients with cancer has
become recognised (Hanahan and Weinberg, 2011) and has
become a hot topic for scientists and clinicians with the terms
cancer and inflammation returning 1179 articles in 2002 compared
with 3693 articles in 2012 (http://www.ncbi.nlm.nih.gov/pubmed/
?term=cancerþ andþ inflammation). Despite the increasing interest,
there remains a paucity of clinical studies showing how such new
information might improve the treatment of symptoms in the
cancer patient.
For a long time, there have been suspicions that cancer-
associated symptoms, in particular the progressive loss of weight
and lean tissue, are manifestations of a chronic ongoing systemic
inflammatory response. Indeed, some early randomised clinical
trial data were consistent with this concept (Lundholm et al, 1994;
McMillan et al, 1999) and provoked reviews to call for further work
on this hypothesis (MacDonald, 2007; McMillan, 2008).
In addition to clear associations with individuals symptoms and
poorer outcome, cancer-associated systemic inflammation is likely
to mitigate administration of other effective treatments. For
example, the efficacy of many current chemotherapeutics are
reliant on metabolic clearance by hepatic cytochrome P450
enzymes, a process which is known to be hindered by ongoing
systemic inflammation, potentially resulting in treatment toxicity
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or failure (Kacevska et al, 2008). Therefore, it is logical that there
should be a stratification on the basis of systemic inflammatory
response measurement within randomised clinical trials of cancer
therapeutics (McMillan, 2013b).
The aim of the present minireview was to examine the evidence
in the last decade for the association of the systemic inflammatory
response with the range of symptoms including appetite loss,
weight loss, fatigue and pain and identify a rational clinical
approach to moderate the systemic inflammatory response and
reduce symptoms experienced in patients with cancer.
MEASUREMENT OF THE SYSTEMIC INFLAMMATORY
RESPONSE
Although activation of the systemic inflammatory response
involves many organ systems, the usual clinical laboratory
measures of the magnitude of activation are circulating white cells
and acute phase proteins (Gabay and Kushner, 1999). Over the last
decade it has become clear that such measurements of an elevated
systemic inflammatory response are consistently associated with
poor outcome independent of tumour stage. In particular, white
cell counts such as neutrophil, lymphocyte and platelet counts and
acute phase proteins, such as C-reactive protein and albumin and
their combinations, neutrophil lymphocyte ratio (NLR), platelet
lymphocyte ratio (PLR) and Glasgow Prognostic Score (GPS)
respectively have been reported repeatedly to have prognostic value
(Roxburgh and McMillan, 2010; Guthrie et al, 2013; McMillan,
2013a). For example, over the last decade, more than 120 studies
(460 000 patients) have examined the clinical utility of the NLR
and/or the GPS to predict patient outcomes in a variety of cancers.
Taken together, these systemic inflammation-based scores can be
considered to represent an upregulation of the innate immune/
inflammatory responses. Irrespective of this, these comprehensive
and compelling data have resulted in calls for such systemic
inflammation-based prognostic scores to be routinely incorporated
into clinical care to improve treatment allocation and the design
of randomised clinical trials (McMillan, 2013b; Douglas and
McMillan, 2013).
RELATIONSHIP BETWEEN SYSTEMIC INFLAMMATORY
RESPONSE, SYMPTOM CLUSTERS AND SURVIVAL
Symptoms associated with cancer are commonly regarded as
natural sequelae to the progression of cancer, that is, due to the
tumour burden. However, it has long been recognised that
progressive involuntary loss of appetite, weight and physical
function are features of advanced disease and aggressive types of
tumour such as lung and pancreatic cancer, independent of the
tumour stage. Similarly, fatigue, pain and depression are all
features of advanced disease. Indeed, in the last decade it has
become clear that the common symptoms such as appetite loss,
weight loss, physical functioning and fatigue and pain are
independently associated with survival in patients with advanced
disease (Trajkovic-Vidakovic et al, 2012; Laird et al, 2013a).
Also, there is now a great deal of evidence, at least in animal
models, of the role of pro-inflammatory cytokines in producing
sickness behaviour that recapitulates many of the symptoms seen
in patients with cancer (Illi et al, 2012). Finally, consistent with this
concept is that symptoms in patients with cancer rarely exist in
isolation but most occur in clusters, three or more symptoms that
are related to each other (Kirkova et al, 2010). In particular, there
are multiple reports that appetite loss, weight loss and physical
function are a symptom cluster (Solheim et al, 2013a) and that
fatigue, pain and depression are another (Laird et al, 2011) in
patients with cancer. These symptom clusters may be considered to
represent in part a neurological response to upregulation of the
innate immune response (Dantzer, 2004). Observations that
advanced disease and aggressive tumours, such as lung and
pancreatic cancer, are associated with a greater activation of the
systemic inflammatory response compared with tumours in which
symptom clusters are rarely seen, such as breast cancer (Proctor
et al, 2010), are consistent with this concept.
Recently in a large international cohort of advanced cancer
patients (n¼ 1466), Laird et al (2013b) reported that C-reactive
protein was significantly associated with all of the function
components of the EORTC QLQ-C30 including cognitive,
physical, role, emotional and social. There was also a significant
association with appetite loss, pain and fatigue. However, it
remains to be clearly established that reduction of markers of the
systemic inflammatory response will be accompanied by a
clinically relevant improvement in symptoms and survival.
Conclusion. The importance of treating cancer-associated symp-
toms has recently been highlighted to oncologists with evidence
that that the administration of routine chemotherapy protocols are
associated with a significant 30-day mortality (NCEPOD, Systemic
Anti-Cancer Therapy: For better, for worse?; http://www.ncepod.
org.uk/2008sact.htm). Furthermore, that early referral to palliative
care for symptom control was associated with not only an
improvement in quality of life but also an improvement in survival
compared with standard care in patients with advanced non-small
cell lung cancer (Temel et al, 2010).
The above literature shows a clear association between the
systemic inflammatory response and cancer-associated symptoms
(see Figure 1 and also in more detail Saligan and Kim, 2012).
Given that activation of the systemic inflammatory response for
most patients is chronic and unremitting, this raises the issue of
how might it be moderated to ameliorate symptoms in the patient
with cancer.
TREATMENT OF CANCER-ASSOCIATED SYMPTOMS IN
PATIENTS WITH ANTI-INFLAMMATORY AGENTS
Owing to the myriad effects of the systemic inflammatory response
in patients with cancer and the established anti-cancer treatments,
it is likely that those anti-inflammatory agents most likely to
make their way into routine clinical practice in the short term
(5–10 years) will be those agents that have a broad brush
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Figure 1. The relationship between the tumour microenvironment
and the host systemic inflammatory response: treat the tumour and
treat the host. .
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anti-inflammatory action and have a low or well-documented side-
effect profile and readily used alongside standard cancer treatments
(some currently used due to comorbid disease). The use of such
anti-inflammatory agents will be guided by measures of the
systemic inflammatory response as described above.
Corticosteroids. Corticosteroids are known to reduce the systemic
inflammatory response, at least in the short term and are
frequently prescribed in advanced cancer for symptom control.
For example, a survey from the USA reported that 33% oncologists
prescribe steroids in the end-of-life care (www.nccn.org, 2013).
Moreover, they have been subject to at least six controlled trials
accounting for more than 1000 patients and have been shown to
improve appetite and quality of life if only for a limited time of a
few weeks. A recent placebo-controlled trial demonstrated that
dexamethasone 4mg per day administered to advanced cancer
patients for just two weeks resulted in significant improvements in
cancer-related symptoms (weight loss, anxiety, fatigue, pain,
nausea, anorexia and depression, Yennurajalingam et al, 2013).
However, unlike other chronic inflammatory diseases, for example,
rheumatoid arthritis, as these drugs have been given empirically in
cancer and not specifically tailored to moderate the systemic
inflammatory response (e.g., C-reactive protein, GPS, NLR or
PLR), it is not clear which corticosteroid should be used nor the
amount and timing of the dosage for optimal and continued
reduction of the systemic inflammatory response.
Non-steroidal anti-inflammatory drugs (NSAIDs). Aspirin and
other NSAIDs inhibit the enzyme cyclooxygenase and the
production of prostaglandins that result in inflammatory responses
and pain. These are used extensively in the populations of the
western world. There has been a longstanding interest in the use of
NSAIDs in the treatment of cancer-associated symptoms
(Lundholm et al, 1994; McMillan et al, 1999). More recently,
there has been further work that supports the routine use of
NSAIDs in treating the most troublesome symptoms associated
with cancer (Madeddu et al, 2012). Solheim et al (2013b) in a
recent systematic review (including 13 controlled trials of NSAIDS
in advanced cancer), reported that 11 studies reported a slowing of
weight loss with 4 studies demonstrating a reduction in measures
of systemic inflammation. There was also evidence that NSAIDs
may improve physical function and patient-reported quality of life
and reduce markers of the systemic inflammatory response.
Together with well-defined systemic inflammatory response
parameters, the broad-spectrum anti-inflammatory properties of
NSAIDs along with their relatively mild side-effect profiles in
patients, make them good agents for the manipulation of cancer-
associated inflammation with or without gastro-protection.
Furthermore, with recent studies demonstrating positive survival
outcomes with aspirin use following surgery for colorectal cancer
dependent on tumour molecular phenotypes (Liao et al, 2012)
and similar work in breast cancer, the role of aspirin/NSAID
treatment looks set to expand to early-stage disease. However, it is
not clear which NSAID should be used nor the amount and timing
of the dosage for optimal and continued reduction of the systemic
inflammatory response.
Statins. Statins are HMG-CoA reductase inhibitors that have had
a major beneficial impact on the natural history of coronary artery
disease in humans. Beyond their cholesterol-lowering properties,
statins exhibit important anti-inflammatory activities (Jain and
Ridker, 2005). For example, in randomised clinical trials,
moderation of the systemic inflammatory response using a statin
has been clearly associated with improved outcomes (Ridker et al,
2008). Furthermore, favourable effects on organ rejection following
heart and renal transplant confirm an important immunomodu-
latory effect. Also, similar to NSAIDs, long-term statin use before
cancer diagnosis is associated with significantly lower-stage
tumours and better long-term survival (e.g., Ng et al, 2011).
CONCLUSION
From the above, therapeutic intervention using nonselective anti-
inflammatory agents has considerable potential to ameliorate the
symptoms associated with cancer and therefore the potential to
improve the quality and quantity of life in these patients. Indeed,
when commenting on the role of NSAIDs in cancer cachexia
Christoffersen (2013) recently stated, ‘It is hard to avoid noting the
striking contrast between the enormous efforts and resources spent
on developing novel and very expensive drugs targeted at signalling
pathways, many of which have turned out to have only marginal
effects, and the lack of good studies trying out the effects of
relatively cheap drugs.’
The current evidence base is such that, in the absence of
definitive mechanisms, the clinical use of the nonselective anti-
inflammatory agents discussed above should be considered in
patients with cancer-associated symptoms and who have a
measurement of an elevated systemic inflammatory response.
There will remain concerns about the well-documented side effects
of routine use of nonselective anti-inflammatory agents, in
particular NSAIDs. However, these should be considered against
the severity of the symptoms and poor outcome associated with a
chronic systemic inflammatory state. Furthermore, the effective-
ness of their use is now readily monitored. Therefore, it can be
readily envisaged that, with monitoring of their anti-inflammatory
effect and potential side effects, such anti-inflammatory agents can
be used alongside standard anti-tumour treatment hence the title
of the present review. Such work should stimulate a new era of
randomised controlled trials of broad-spectrum anti-inflammatory
agents to provide definitive clinical protocols to improve the
quantity and quality of life of the patient with cancer.
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